Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive factors for neoadjuvant combined immunotherapy in gastric adenocarcinoma: Focusing on the primitive enterocyte phenotype and PVR.

British journal of cancer - 1 Aug 2025

Wang Bingzhi, Wang Yinong, Zhu Yongjian, Guo Lei, Zeng Hua, Wu Shuai, Wang Long, Mu Jiali, Shao Xinxin, Cheng Na, Ying Jianming, Tian Yantao, Xue Liyan

Abstract excerpt

BACKGROUND: Neoadjuvant combined immunotherapy has provided more treatment options for patients with gastric adenocarcinoma (GA). However, some GA patients, especially those with primitive enterocyte phenotype (GAPEP) show a poor response to immunotherapy, even with positive PD-L1 expression. METHOD: We enrolled multiple cohorts from our center and utilized public data to identify the predictive factors and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Biomarkers, Tumor

Share to Immunotherapy

Share to Neoadjuvant Therapy

Share to Prognosis

Share to Stomach Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 40341250
DOI: 10.1038/s41416-025-03031-3
PMCID: PMC12304217

Genes

PVR
GZMA
PRF1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive factors for neoadjuvant combined immunotherapy in gastric adenocarcinoma: Focusing on the primitive enterocyte phenotype and PVR.PMID 40341250Read ↗

Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysisSemantic proximity Read ↗

Comprehensively prognostic and immunological analyses of GLP-1 signaling-related genes in pan-cancer and validation in colorectal cancerSemantic proximity Read ↗

Elevated neutrophil-to-lymphocyte ratio induced by tumor and immune cells promotes gastric cancer progression during PD-1 antibody-based treatmentSemantic proximity Read ↗

Sequential pembrolizumab cooperates with platinum/5FU to remodel the tumor microenvironment in advanced gastric cancer: a phase II chemoimmunotherapy trialSemantic proximity Read ↗

IFIT1 + neutrophil is a causative factor of immunosuppressive features of poorly cohesive carcinoma (PCC)Semantic proximity Read ↗

Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II TrialSemantic proximity Read ↗

GARP Correlates With Tumor-Infiltrating T-Cells and Predicts the Outcome of Gastric CancerSemantic proximity Read ↗

Implications of PD-L1 expression on the immune microenvironment in HER2-positive gastric cancerSemantic proximity Read ↗

Intertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumorsSemantic proximity Read ↗

Proliferative and quiescent human gastric cancer stem-like cells are associated with differential chemoresistance and patient mortalitySemantic proximity Read ↗

Neoadjuvant Combination Immunotherapy for Colorectal Cancer: Clinical and Molecular Predictors of Pathological Complete Response and Safety AssessmentSemantic proximity Read ↗

Immunotherapy for gastric cancer: dilemmas and prospectSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.